Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

NCT02199496 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

5

Enrollment

NIH

Sponsor class

Conditions

Gastrointestinal Inflammation Associated With CVID
CVID Enteropathy

Interventions

BIOLOGICAL: Stelara (ustekinumab)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)